Acopair - Tiotropium
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
The professional's guide to product selection
The professional's guide to product selection
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
Long-acting selective beta2 agonist with corticosteroid.
AirFluSal 125
• Adult for prophylaxis of moderate to severe asthma: two inhalations twice daily.
AirFluSal 250
• Over 18 years for prophylaxis of moderate to severe asthma: two inhalations twice daily.
AirFluSal Forspiro
• Adult for severe asthma and COPD: one inhalation twice a day.
Short-acting selective beta2 agonist.
Inhaled
• Child, by aerosol inhalation: 100 mcg (1 puff), increased to 200 mcg (2 puffs) if necessary. For persistent symptoms, up to four times daily.
• Adult, by aerosol inhalation: 100–200 mcg (1–2 puffs), for persistent symptoms up to 4 times daily.
• Adult, by inhalation of nebulised solution: 2.5–5 mg, repeated up to four times daily for persistent symptoms.
Moderate and severe acute asthma by inhalation of aerosol.
• Children and adults: 2–10 puffs, each puff to be inhaled separately, repeat every 10–20 minutes or when required. Each puff is equivalent to 100 mcg.
Long-acting selective beta2 agonist with corticosteroid.
Prophylaxis of moderate-to-severe asthma for Aloflute® 25/125 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Prophylaxis of moderate-to-severe asthma for Aloflute® 25/250 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Antimuscarinic bronchodilator with long-acting selective beta2 agonist.
• Adult over 18 years for maintenance treatment of COPD: by inhalation of powder, 1 inhalation, once daily.
Long-acting selective beta2 agonist with corticosteroid.
For prophylaxis of asthma
Atectura Breezhaler 125/62.5
Atectura Breezhaler 125/260
Atectura Breezhaler 125/127.5
Adult: one inhalation once daily.
Long-acting selective beta2 agonist.
Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy
Nocturnal asthma in patients requiring long-term regular bronchodilator therapy
Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
Chronic asthma in patients who regularly use an inhaled corticosteroid
By inhalation of powder:
• Child 6-11 years: 12 mcg twice daily should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily.
By inhalation of aerosol:
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily, dose may be increased in more severe airway obstruction; increased to 24 mcg twice daily.
COPD
By inhalation of powder
• Adult: 12 mcg twice daily
By inhalation of aerosol
• Adult: 12 mcg twice daily (maximum per dose 24 mcg). If required, additional doses up to a maximum of 48 mcg per day can be taken.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
For prophylaxis of asthma with Avenor® 25/125 by inhalation of aerosol
Child 12–17 years: 2 inhalations twice daily.
Adult: 2 inhalations twice daily.
For prophylaxis of asthma with Avenor® 25/250 by inhalation of aerosol
Child 12–17 years: 2 inhalations twice daily.
Adult: 2 inhalations twice daily.
For prophylaxis of asthma with Avenor® 25/50 by inhalation of aerosol
Child 4–17 years: 2 inhalations twice daily, reduced to 2 inhalations once daily, use reduced dose only if control maintained.
Adult: 2 inhalations twice daily, reduced to 2 inhalations once daily, use reduced dose only if control maintained.
Long-acting muscarinic antagonist, Long-acting beta 2 agonist.
Adult: two inhalations twice daily.
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD: by inhalation of powder, one capsule, once daily.
Short-acting selective beta2 agonist.
For asthma
By mouth
Adult: 2.5 mg 3 times a day for 1–2 weeks, then increased to up to 5 mg 3 times a day, use by inhalation preferred over by mouth.
By subcutaneous injection, or slow intravenous injection
Adult:250–500 micrograms up to 4 times a day, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.
By continuous intravenous infusion
Adult: 90–300 micrograms/hour for 8-10 hours, to be administered as a solution containing 3–5 micrograms/mL, high doses require close monitoring, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect.
By inhalation of powder
Adult: 500 micrograms up to 4 times a day, for persistent symptoms.
By inhalation of nebulised solution
Adult: 5–10 mg 2–4 times a day, additional doses may be necessary in severe acute asthma.
For acute asthma
By subcutaneous injection, or by slow intravenous injection
• Child 2–14 years: 10 mcg/kg up to four times/day (maximum per dose 300 mcg)
• Child 15–17 years: 250–500 mcg up to four times/day
By continuous intravenous infusion
• Child: loading dose of 2–4 mcg/kg, then 1–10 mcg/kg/hour
For moderate, severe, or life-threatening acute asthma (given via oxygen-driven nebuliser if available)
• Child 1 month–4 years: 5 mg, repeated every 20–30 minutes or when required.
• Child 5–11 years: 5–10 mg, repeated every 20–30 minutes or when required.
• Over 12 years: 10 mg, repeated every 20–30 minutes or when required.
Exacerbation of reversible airway obstruction (including nocturnal asthma), prevention of exercise-induced bronchospasm
By inhalation of powder
• Child 5–17 years: 500 mcg up to four times/day
By mouth
• Child 1 month–6 years: 75 mcg/kg three times/day (maximum per dose 2.5 mg)
• Child 7–14 years: 2.5 mg 2–3 times daily
• Child 15–17 years: 2.5 mg three times/day, then increased if necessary to 5 mg three times/day.
Antimuscarinic bronchodilator with short-acting selective beta2 agonist.
• Adult and child over 12 years for bronchospasm in chronic obstructive pulmonary disease: by inhalation of nebulised solution, 0.5/2.5 mg, 3–4 times daily.
Ipratropium with short-acting selective beta2 agonist.
For the treatment of bronchospasm in COPD
Adult: 0.5/2.5 mg 3–4 times a day.
Long-acting selective beta2 agonist with corticosteroid.
Combisal 25/125
• Over 12 years for prophylaxis of asthma: two inhalations twice daily.
Combisal 25/50
• Over 4 years for prophylaxis of asthma: two inhalations twice daily, but can be reduced to two inhalations once daily.
Combisal 25/250
• Over 12 years for prophylaxis of asthma: two inhalations twice daily.
Ipratropium with short-acting selective beta2 agonist.
For adult: 0.5/2.5 mg 3–4 times a day.
Long-acting selective beta2 agonist with long-acting muscarinic antagonist.
Adult: one inhalation twice daily.
Long-acting selective beta2 agonist with corticosteroid.
DuoResp Spiromax 160 mcg/4.5 mcg
• Adult for asthma maintenance: one to two inhalations twice daily, and up to four inhalations twice daily.
• Adult for asthma maintenance and reliever therapy: two inhalations twice daily across one or two doses, and increased to two inhalations twice daily if needed. One inhalation taken as required to relieve symptoms and increased up to six if needed but with a maximum of eight inhalations per day. Up to 12 inhalations can be taken per day for a limited time under medical supervision.
• Adult for COPD: two inhalations twice daily.
DuoResp Spiromax 320 mcg/9 mcg
• Adult for asthma maintenance: one inhalation twice daily, but increased to two inhalations twice daily if required.
• Adult for COPD: one inhalation twice daily.
Short-acting selective beta2 agonist.
Inhaled
• Child, by aerosol inhalation: 100 mcg (1 puff), increased to 200 mcg (2 puffs) if necessary. For persistent symptoms, up to four times daily.
• Adult, by aerosol inhalation: 100–200 mcg (1–2 puffs), for persistent symptoms up to 4 times daily.
• Adult, by inhalation of nebulised solution: 2.5–5 mg, repeated up to four times daily for persistent symptoms.
Moderate and severe acute asthma by inhalation of aerosol.
• Children and adults: 2–10 puffs, each puff to be inhaled separately, repeat every 10–20 minutes or when required. Each puff is equivalent to 100 mcg.
Antimuscarinic bronchodilator.
• Over 18 years: by inhalation of powder, 375 mcg (1 inhalation), twice daily.
Long acting muscarinic antagonist, long-acting selective beta2 agonist with corticosteroid.
For prophylaxis of asthma
Adult: one inhalation once daily.
A non-specific adrenoceptor agonist.
By mouth for reversible airway obstruction
• Adult: 15–60 mg, three times daily
By intranasal administration for nasal congestion, sinusitis affecting the maxillary antrum
• Over 12 years: apply 1–2 drops up to four times per day in each nostril for a maximum of seven days
A non-specific adrenoceptor agonist.
For reversible airway obstruction by mouth
Adult: 15–60 mg 3 times a day.
Nasal congestion, sinusitis affecting the maxillary antrum by intranasal administration
Child 12-17 years: Apply 1–2 drops up to 4 times a day as required for a maximum of 7 days, to be instilled into each nostril, administer ephedrine 0.5% nasal drops.
Adult: Apply 1–2 drops up to 4 times a day as required for a maximum of 7 days, to be instilled into each nostril.
A non-specific adrenoceptor agonist.
By mouth for reversible airway obstruction
• Adult: 15–60 mg, three times daily
By intranasal administration for nasal congestion, sinusitis affecting the maxillary antrum
• Over 12 years: apply 1–2 drops up to four times per day in each nostril for a maximum of seven days
A non-specific adrenoceptor agonist.
By mouth for reversible airway obstruction
• Adult: 15–60 mg, three times daily
By intranasal administration for nasal congestion and sinusitis affecting the maxillary atrum
• Child 12-17 years: Apply 1–2 drops up to 4 times a day as required for a maximum of 7 days, to be instilled into each nostril, administer ephedrine 0.5% nasal drops.
• Adult: Apply 1–2 drops up to 4 times a day as required for a maximum of 7 days, to be instilled into each nostril.
A non-specific adrenoceptor agonist.
By mouth for reversible airway obstruction
• Adult: 15–60 mg, three times daily
By intranasal administration for nasal congestion, sinusitis affecting the maxillary antrum
• Over 12 years: apply 1–2 drops up to four times per day in each nostril for a maximum of seven days
A non-specific adrenoceptor agonist.
By mouth for reversible airway obstruction
• Adult: 15–60 mg, three times daily
By intranasal administration for nasal congestion, sinusitis affecting the maxillary antrum
• Over 12 years: apply 1–2 drops up to four times per day in each nostril for a maximum of seven days
A non-specific adrenoceptor agonist.
By mouth for reversible airway obstruction
• Adult: 15–60 mg, three times daily
By intranasal administration for nasal congestion, sinusitis affecting the maxillary antrum
• Over 12 years: apply 1–2 drops up to four times per day in each nostril for a maximum of seven days
A non-specific adrenoceptor agonist.
For reversible airway obstruction by mouth
Adult: 15–60 mg 3 times a day.
Nasal congestion, sinusitis affecting the maxillary antrum by intranasal administration
Child 12-17 years: Apply 1–2 drops up to 4 times a day as required for a maximum of 7 days, to be instilled into each nostril, administer ephedrine 0.5% nasal drops.
Adult: Apply 1–2 drops up to 4 times a day as required for a maximum of 7 days, to be instilled into each nostril.
A non-specific adrenoceptor agonist.
By mouth for reversible airway obstruction
• Adult: 15–60 mg, three times daily
By intranasal administration for nasal congestion and sinusitis affecting the maxillary atrum
• Child 12-17 years: Apply 1–2 drops up to 4 times a day as required for a maximum of 7 days, to be instilled into each nostril, administer ephedrine 0.5% nasal drops.
• Adult: Apply 1–2 drops up to 4 times a day as required for a maximum of 7 days, to be instilled into each nostril.
Long-acting selective beta2 agonist with corticosteroid.
Fixkoh Airmaster 50/100
• 12 years and over for prophylaxis of asthma: one inhalation twice daily but can be reduced to once daily.
Fixkoh Airmaster 50/250
• 12 years and over for prophylaxis of asthma: one inhalation twice daily.
Fixkoh Airmaster 50/500
• 12 years and over for prophylaxis of asthma: one inhalation twice daily.
• Adult for COPD: 1 inhalation twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Flutiform 50
• Over 5 years for prophylaxis of asthma: two puffs twice daily.
Flutiform 125
• Over 12 years by aerosol inhalation for prophylaxis of asthma: two puffs twice daily.
Flutiform 250
• Adult for prophylaxis of asthma: two puffs twice daily.
Flutiform K-haler 50
• Over 12 years by aerosol inhalation for prophylaxis of asthma: two puffs twice daily.
Flutiform K-haler 125
• Over 12 years by aerosol inhalation for prophylaxis of asthma: two puffs twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Fobumix 80/4.5 Easyhaler
• Adult for asthma maintenance: one to two inhalations twice daily, but increased to four inhalations twice daily if required.
• Adult for asthma maintenance and relief therapy: two inhalations daily across one or two doses. One inhalation can be used for relief of symptoms up to six doses with a maximum of eight per day. Twelve doses can be administered per day for a short time under medical supervision.
Fobumix 160/4.5 Easyhaler
• Adult for asthma maintenance: one to two inhalations twice daily, but increased to four inhalations twice daily if required.
• Adult for asthma maintenance and relief therapy: two inhalations daily across one or two doses, increased to two inhalations twice daily if needed. One inhalation can be used for relief of symptoms up to six doses with a maximum of eight per day. Twelve doses can be administered per day for a short time under medical supervision.
• Adult for COPD: two inhalations twice daily.
Fobumix 320/9 Easyhaler
• Adult for asthma maintenance: one inhalation twice daily, but increased to two inhalations twice daily if required.
• Adult for COPD: one inhalation twice daily.
Long-acting selective beta2 agonist.
Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy
Norctornal asthma in patients requiring long-term regular bronchodilator therapy
Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
Chronic asthma in patients who regularly use an inhaled corticosteroid
By inhalation of powder:
• Child 6-11 years: 12 mcg twice daily should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily.
By inhalation of aerosol:
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily, dose may be increased in more severe airway obstruction; increased to 24 mcg twice daily.
COPD
By inhalation of powder
• Adult: 12 mcg twice daily
By inhalation of aerosol
• Adult: 12 mcg twice daily (maximum per dose 24 mcg). If required, additional doses up to a maximum of 48 mcg per day can be taken.
Long-acting selective beta2 agonist.
Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy
Norctornal asthma in patients requiring long-term regular bronchodilator therapy
Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
Chronic asthma in patients who regularly use an inhaled corticosteroid
By inhalation of powder:
• Child 6-11 years: 12 mcg twice daily should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily.
By inhalation of aerosol:
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily, dose may be increased in more severe airway obstruction; increased to 24 mcg twice daily.
COPD
By inhalation of powder
• Adult: 12 mcg twice daily
By inhalation of aerosol
• Adult: 12 mcg twice daily (maximum per dose 24 mcg). If required, additional doses up to a maximum of 48 mcg per day can be taken.
Long-acting selective beta2 agonist with corticosteroid.
Fostair NEXThaler 200/6
• Adult for asthma maintenance therapy: two inhalations twice daily, with a maximum of four inhalations per day.
Fostair NEXThaler 100/6
• Adult for asthma maintenance therapy: one to two inhalations twice daily, with a maximum of four inhalations per day.
• Adult for asthma maintenance and reliever therapy: one inhalations twice daily, with a maximum of eight inhalations per day.
• Adult for COPD with FEV1 <50% predicted: two inhalations twice daily.
Fostair 100/6
• Adult for asthma maintenance therapy: one to two inhalations twice daily, with a maximum of four inhalations per day.
• Adult for asthma maintenance and reliever therapy: one inhalations twice daily, with a maximum of eight inhalations per day.
• Adult for COPD with FEV1 <50% predicted: two inhalations twice daily.
Fostair 200/6
• Adult for asthma maintenance therapy: two inhalations twice daily, with a maximum of four inhalations per day.
Long-acting selective beta2 agonist with corticosteroid.
Fusacomb 50/250 Easyhaler
• 12 years and over for prophylaxis of asthma: one inhalation twice daily and can be reduced to once daily.
Fusacomb 50/500 Easyhaler
• 12 years and over for prophylaxis of asthma: one inhalation twice daily.
• Adult for COPD: one inhalation twice daily.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
In the case of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 micrograms every 4 hours and when required, hourly use is occasionally necessary.
In the case of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
Antimuscarinic bronchodilator.
For excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
By subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
for maintenance treatment of chronic obstructive pulmonary disease by inhalation of powder
Adult: 1 capsule once daily, each capsule delivers 55 mcg of glycopyrronium bromide (equivalent to 44 mcg of glycopyrronium).
Antimuscarinic bronchodilator.
• Over 18 years for COPD: by inhalation of powder, 55 mcg (1 inhalation), once daily.
Antimuscarinic bronchodilator with short-acting selective beta2 agonists.
• Adult and child over 12 years for bronchospasm in chronic obstructive pulmonary disease: by inhalation of nebulised solution, 0.5/2.5 mg, 3–4 times daily.
Ipratropium with short-acting selective beta2 agonist.
For adult: 0.5/2.5 mg 3–4 times a day.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Acute bronchospasm by inhalation of nebulised solution
• Child under 5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Severe or life-threatening acute asthma
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Antimuscarinic bronchodilator.
Reversible airway obstruction by inhalation of aerosol
• Child 1 month–5 years: 20 mcg, 3 times daily.
• Child 6–11 years: 20–40 mcg, 3 times daily.
• Over 12 years: 20–40 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of nebulised solution
• Adult: 250–500 mcg, 3–4 times daily.
For reversible airways obstruction in COPD by inhalation of aerosol
• Adult: 20–40 mcg, 3–4 times daily.
Severe or life-threatening acute asthma by inhalation of nebulised solution
• Child 1 month–11 years: 250 mcg, every 20–30 minutes, for the first two hours, then repeat every 4–6 hours, as required.
• Over 12 years: 500 mcg, every 4–6 hours, as required.
Acute bronchospasm by inhalation of nebulised solution
• Child 1 month–5 years: 125–250 mcg, maximum 1 mg daily.
• Child 6–11 years: 250 mcg, maximum 1 mg daily.
• Over 12 years: 500 mcg, repeated as necessary, usual maximum 2 mg daily. Doses higher than the recommended maximum can be given under medical supervision.
Rhinorrhoea associated with allergic and non-allergic rhinitis by intranasal administration
• Over 12 years: 2 sprays, 2–3 times/day into each nostril.
Long-acting selective beta2 agonist with corticosteroid.
Asthma maintenance therapy for Luforbec® 100/6 by inhalation of aerosol
Adult: 1–2 inhalations twice daily; maximum 4 inhalations per day.
Asthma, maintenance and reliever therapy for Luforbec® 100/6 by inhalation of aerosol
Adult: 1 inhalation twice daily; 1 inhalation as required, for relief of symptoms; maximum 8 inhalations per day.
Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 50% of predicted for Luforbec® 100/6 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Asthma maintenance therapy for Luforbec® 200/6 by inhalation of aerosol
Adult: 2 inhalations twice daily, maximum 4 inhalations per day.
Children and adolescents aged less than 18 years must not take this medicine
Long-acting selective beta2 agonist.
Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy
Nocturnal asthma in patients requiring long-term regular bronchodilator therapy
Prevention of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
Chronic asthma only in patients who regularly use an inhaled corticosteroid (not for immediate relief of acute asthma)
By inhalation of aerosol, or by inhalation of powder
• Child 5–11 years: 50 mcg, twice daily.
• Over 12 years: by inhalation, 50 mcg twice daily. Up to 100 mcg twice daily for more severe airway obstruction.
For COPD by inhalation of aerosol, or by inhalation of powder
• Adult: 50 mcg (2 puffs or 1 blister), twice daily.
Long-acting selective beta2 agonist.
• Over 18 years, by inhalation of powder: 150 mcg, once daily, increased to a maximum of 300 mcg once daily.
Long-acting selective beta2 agonist.
Oxis
By inhalation of powder for chronic asthma
• 6–17 years: 6–12 micrograms 1–2 times a day (max. per dose 12 micrograms), occasionally doses up to the maximum daily may be needed, reassess treatment if additional doses required on more than 2 days a week; maximum 48 micrograms per day.
• Adult: 6–12 micrograms 1–2 times a day, increased if necessary up to 24 micrograms twice daily (max. per dose 36 micrograms), occasionally doses up to the maximum daily may be needed, reassess treatment if additional doses required on more than 2 days a week; maximum 72 micrograms per day.
By inhalation of powder for relief of bronchospasm
• Over 6 years: 6–12 mcg up to twice daily
By inhalation of powder for prophylaxis of exercise-induced asthma
• Over 6 years: 6–12 mcg before exercise
• Adult: 12 mcg before exercise
By inhalation powder for COPD
• Adult: 12 micrograms 1–2 times a day (max. per dose 24 micrograms), for symptom relief additional doses up to maximum daily dose can be taken; maximum 48 micrograms per day.
Long-acting selective beta2 agonist with corticosteroid.
Relvar Ellipta 92 mcg/22 mcg
• Over 12 years for prophylaxis of asthma: one inhalation once daily.
• Adult for COPD: one inhalation once daily.
Relvar Ellipta 184 mcg/22 mcg
• Over 12 years for prophylaxis of asthma: one inhalation once daily.
Short-acting selective beta2 agonist.
For acute bronchospasm, Salbulin Novolizer® by inhalation of powder
Adult: Initially 100–200 micrograms, up to 800 micrograms daily for persistent symptoms.
For prophylaxis of allergen- or exercise-induced bronchospasm, Salbulin Novolizer® by inhalation of powder
Adult: 200 micrograms.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Short-acting selective beta2 agonist.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Short-acting selective beta2 agonist.
Injection
• Child 1–23 months, by intravenous injection over 5 minutes: 5 mcg/kg as a single dose.
• Child 2–17 years, by intravenous injection over 5 minutes: 15 mcg/kg (maximum 250 mcg) as a single dose.
• Adult, subcutaneous or intramuscular injection: 500 mcg, repeated every four hours if necessary.
• Adult, by slow intravenous injection: (dilute to a concentration of 50 mcg/ml), 250 mcg, repeated if necessary.
Infusion
• Child 1 month–18 years: 1–2 mcg/kg/minute, adjusted according to response and heart rate, up to 5 mcg/kg/minute. Doses above 2 mcg/kg/minute should be given in an intensive care setting.
• Adult, by intravenous infusion: initially 5 mcg/minute, adjusted according to response and heart rate, usually in range 3–20 mcg/minute, or more if necessary.
Inhaled
• Child, by aerosol inhalation: 100 mcg (1 puff), increased to 200 mcg (2 puffs) if necessary. For persistent symptoms, up to four times daily.
• Adult, by aerosol inhalation: 100–200 mcg (1–2 puffs), for persistent symptoms up to 4 times daily.
• Adult, by inhalation of nebulised solution: 2.5–5 mg, repeated up to four times daily for persistent symptoms.
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Moderate and severe acute asthma by inhalation of aerosol.
• Children and adults: 2–10 puffs, each puff to be inhaled separately, repeat every 10–20 minutes or when required. Each puff is equivalent to 100 mcg.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Short-acting selective beta2 agonist.
Injection
• Child 1–23 months, by intravenous injection over 5 minutes: 5 mcg/kg as a single dose.
• Child 2–17 years, by intravenous injection over 5 minutes: 15 mcg/kg (maximum 250 mcg) as a single dose.
• Adult, subcutaneous or intramuscular injection: 500 mcg, repeated every four hours if necessary.
• Adult, by slow intravenous injection: (dilute to a concentration of 50 mcg/ml), 250 mcg, repeated if necessary.
Infusion
• Child 1 month–18 years: 1–2 mcg/kg/minute, adjusted according to response and heart rate, up to 5 mcg/kg/minute. Doses above 2 mcg/kg/minute should be given in an intensive care setting.
• Adult, by intravenous infusion: initially 5 mcg/minute, adjusted according to response and heart rate, usually in range 3–20 mcg/minute, or more if necessary.
Inhaled
• Child, by aerosol inhalation: 100 mcg (1 puff), increased to 200 mcg (2 puffs) if necessary. For persistent symptoms, up to four times daily.
• Adult, by aerosol inhalation: 100–200 mcg (1–2 puffs), for persistent symptoms up to 4 times daily.
• Adult, by inhalation of nebulised solution: 2.5–5 mg, repeated up to four times daily for persistent symptoms.
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Moderate and severe acute asthma by inhalation of aerosol.
• Children and adults: 2–10 puffs, each puff to be inhaled separately, repeat every 10–20 minutes or when required. Each puff is equivalent to 100 mcg.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Antimuscarinic bronchodilator.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.
For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.
For prophylaxis of asthma with Seffalair Spiromax® 12.75/100 by inhalation of powder
Child 12–17 years: 1 inhalation twice daily.
Adult: 1 inhalation twice daily.
For prophylaxis of asthma with Seffalair Spiromax® 12.75/202 by inhalation of powder
Child 12–17 years: 1 inhalation twice daily.
Adult: 1 inhalation twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Sereflo Ciphaler 50/250 for prophylaxis of asthma
• Over 12 years: 1 inhalation twice daily, reduced to 1 inhalation once daily, use reduced dose only if control maintained.
Sereflo 125
• Adult for moderate to severe asthma: two inhalations twice daily.
Sereflo 250
• Adult moderate to severe asthma: two inhalations twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Seretide 100 Accuhaler
• 4 years and over for asthma prophylaxis: one inhalation twice daily, reduce to one inhalation daily if controlled.
Seretide 250 Accuhaler
• 12 years and over for asthma prophylaxis: one inhalation twice daily.
Seretide 500 Accuhaler
• 12 years and over for asthma prophylaxis: one inhalation twice daily.
• Adult for COPD with FEV1 in one second <60% of predicted: one inhalation twice daily.
Seretide 50 Evohaler
• 4 years and over for asthma prophylaxis: two puffs twice daily, reduce to two puffs once daily if controlled.
Seretide 125 Evohaler
• 12 years and over for asthma prophylaxis: two puffs twice daily.
Seretide 250 Evohaler
• 12 years and over for asthma prophylaxis: two puffs twice daily.
Long-acting selective beta2 agonist.
Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy
Nocturnal asthma in patients requiring long-term regular bronchodilator therapy
Prevention of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
Chronic asthma only in patients who regularly use an inhaled corticosteroid (not for immediate relief of acute asthma)
By inhalation of aerosol, or by inhalation of powder
• Child 5–11 years: 50 mcg, twice daily.
• Over 12 years: by inhalation, 50 mcg twice daily. Up to 100 mcg twice daily for more severe airway obstruction.
For COPD by inhalation of aerosol, or by inhalation of powder
• Adult: 50 mcg (2 puffs or 1 blister), twice daily.
Long-acting selective beta2 agonist
Reversible airways obstruction in patients requiring long-term regular broncodilator therapy
Nocturnal asthma in patients requiring long-term regular bronchodilator therapy
Prevention of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
Chronic asthma only in patients who regularly use inhaled corticosteroid (not for immediate relief of acute asthma)
• Child 5–11 years: 50 mcg, twice daily.
• Over 12 years: by inhalation, 50 mcg twice daily. Up to 100 mcg twice daily for more severe airway obstruction.
For COPD
• Adult: 50 mcg, twice daily.
Antimuscarinic bronchodilator with long-acting selective beta2 agonist.
• Over 18 years for maintenance treatment of COPD: by inhalation of aerosol, two puffs once daily.
Antimuscarinic bronchodilator.
• Over 18 years for maintenance of COPD or treatment of asthma using Spiriva Respimat: by inhalation, 5 mcg, once daily.
• Child 6-11 years for severe asthma [add-on to inhaled corticosteroid (over 400 micrograms budesonide daily or equivalent) and 1 controller, or inhaled corticosteroid (200–400 micrograms budesonide daily or equivalent) and 2 controllers, in patients who have suffered one or more severe exacerbations in the last year]: 5 mcg, once daily.
• Child 12-17 years for severe asthma [add-on to inhaled corticosteroid (over 800 micrograms budesonide daily or equivalent) and 1 controller, or inhaled corticosteroid (400–800 micrograms budesonide daily or equivalent) and 2 controllers, in patients who have suffered one or more severe exacerbations in the last year]: 5 mcg, once daily.
For severe asthma in patients 12 years of age and older only where use of a combination product (long-acting beta2 agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled on a lower strength corticosteroid combination product or patients already adequately controlled on an inhaled corticosteroid in a high strength and a long-acting beta2 agonist.
For symptomatic treatment of COPD with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Long-acting selective beta2 agonist.
• Over 18 years by inhalation: 5 mcg (2 puffs), once daily.
Long-acting selective beta2 agonist with corticosteroid.
Symbicort 100/3 pressurised inhaler
Asthma, maintenance therapy
• Child 12–17 years: Initially 2–4 inhalations twice daily; reduced to 1 inhalation daily, dose reduced only if control is maintained.
• Adult: Initially 2–4 inhalations twice daily, increased if necessary up to 8 inhalations twice daily; reduced to 1 inhalation daily, dose reduced only if control is maintained.
Asthma, maintenance and reliever therapy
• Over 12 years: Maintenance 4 inhalations daily in 1–2 divided doses, increased if necessary up to 4 inhalations twice daily; 2 inhalations as required for relief of symptoms, increased if necessary up to 12 inhalations as required, usual max. 16 inhalations per day; up to 24 inhalations daily can be used for a limited time under medical supervision.
Symbicort 200/6 Pressurised inhaler
COPD
• Adult: 2 inhalations twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Symbicort 100/6 Turbohaler
• 6–17 years for asthma maintenance: 1-2 inhalations twice daily, reduced to 1 inhalation daily if controlled.
• Adults for asthma maintenance: 1-2 inhalations daily, increased to up to 4 inhalations daily if needed, or reduced to 1 daily if controlled.
• Over 12 years for asthma maintenance and reliever therapy: 2 inhalations daily across one or two doses; 1 inhalation for relief of symptoms and increase to 6 if required. A maximum of 8 inhalations per day, but 12 can be given under medical supervision.
Symbicort 200/6 Turbohaler
• 12–17 years for asthma maintenance: 1-2 inhalations twice daily, reduced to 1 inhalation daily if controlled.
• Adults for asthma maintenance: 1-2 inhalations daily, increased to up to 4 inhalations daily if needed, or reduced to one daily if controlled.
• Over 12 years for asthma maintenance and reliever therapy: 2 inhalations daily across one or two doses but can be increased to 2 inhalations twice daily if needed; 1 inhalation for relief of symptoms and increase to 6 inhalations if required. A maximum of 8 inhalations per day, but 12 can be given for a limited time under medical supervision.
• Adult for COPD: 1 inhalation twice daily.
Symbicort 400/12 Turbohaler
• 12–17 years for asthma maintenance: 1 inhalation twice daily, but can be reduced to 1 inhalation daily.
• Adult for asthma maintenance: 1 inhalation twice daily, increased to 2 inhalations twice daily if required and decreased to 1 inhalation daily if controlled.
• Adult for COPD: 1 inhalation twice daily.
By inhalation of nebulised solution for asthma
• Over 12 years: 5–10 mg 2–4 times daily, additional doses may be necessary in severe acute asthma.
By inhalation of nebulised solution for moderate to severe acute asthma
• Child 1 month–4 years: 5 mg, repeat every 20–30 minutes or as required
• Child 5–11 years: 5–10 mg, repeat every 20–30 minutes or as required
• Over 12 years: 10 mg, repeat every 20–30 minutes or as required
Short-acting selective beta2 agonist.
By inhalation of nebulised solution for asthma
• Over 12 years: 5–10 mg 2–4 times daily, additional doses may be necessary in severe acute asthma.
By inhalation of nebulised solution for moderate to severe acute asthma
• Child 1 month–4 years: 5 mg, repeat every 20–30 minutes or as required
• Child 5–11 years: 5–10 mg, repeat every 20–30 minutes or as required
• Over 12 years: 10 mg, repeat every 20–30 minutes or as required
By inhalation of nebulised solution for asthma
• Over 12 years: 5–10 mg 2–4 times daily, additional doses may be necessary in severe acute asthma.
By inhalation of nebulised solution for moderate to severe acute asthma
• Child 1 month–4 years: 5 mg, repeat every 20–30 minutes or as required
• Child 5–11 years: 5–10 mg, repeat every 20–30 minutes or as required
• Over 12 years: 10 mg, repeat every 20–30 minutes or as required
Adults for maintenance bronchodilator treatment to relieve symptoms of patients with COPD by inhalation of powder, one capsule, once daily.
Long-acting muscarinic receptor antagonist, long-acting selective beta2 agonist with corticosteroid.
Trimbow 87/5/9 for moderate to severe COPD or asthma maintenance therapy
Adult: 2 inhalations twice daily.
Trimbow 172/5/9 for asthma maintenance therapy
Adult: 2 inhalations twice daily.
Trimbow NEXThaler 88/5/9 for moderate to severe COPD
Adult: 2 inhalations twice daily.
Long acting muscarinic antagonist, long-acting beta 2 agonist and inhaled corticosteroid.
Two inhalations twice daily
Antimuscarinic bronchodilator with long-acting selective beta2 agonist.
• Adult for maintenance treatment of COPD: by inhalation of powder, 1 inhalation, once daily.
Antimuscarinic bronchodilator with long-acting selective beta2 agonist.
• Adult over 18 years for maintenance treatment of COPD: by inhalation of powder, 1 inhalation, once daily.
Short-acting selective beta2 agonist.
Injection
• Child 1–23 months, by intravenous injection over 5 minutes: 5 mcg/kg as a single dose.
• Child 2–17 years, by intravenous injection over 5 minutes: 15 mcg/kg (maximum 250 mcg) as a single dose.
• Adult, subcutaneous or intramuscular injection: 500 mcg, repeated every four hours if necessary.
• Adult, by slow intravenous injection: (dilute to a concentration of 50 mcg/ml), 250 mcg, repeated if necessary.
Infusion
• Child 1 month–18 years: 1–2 mcg/kg/minute, adjusted according to response and heart rate, up to 5 mcg/kg/minute. Doses above 2 mcg/kg/minute should be given in an intensive care setting.
• Adult, by intravenous infusion: initially 5 mcg/minute, adjusted according to response and heart rate, usually in range 3–20 mcg/minute, or more if necessary.
Inhaled
• Child, by aerosol inhalation: 100 mcg (1 puff), increased to 200 mcg (2 puffs) if necessary. For persistent symptoms, up to four times daily.
• Adult, by aerosol inhalation: 100–200 mcg (1–2 puffs), for persistent symptoms up to 4 times daily.
• Adult, by inhalation of nebulised solution: 2.5–5 mg, repeated up to four times daily for persistent symptoms.
Moderate to severe or life-threatening acute asthma, treated by inhalation of nebulised solution. Give via a large volume spacer, and via a close-fitting face mask in children under 3 years.
• Child 1 month–4 years: 2.5 mg, repeat every 20–30 minutes or when required.
• Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required.
• Over 12 years: 5 mg, repeat every 20–30 minutes or when required.
Moderate and severe acute asthma by inhalation of aerosol.
• Children and adults: 2–10 puffs, each puff to be inhaled separately, repeat every 10–20 minutes or when required. Each puff is equivalent to 100 mcg.
Oral
(Please note, inhalation route preferred over oral route in children.)
• Child 1 month–1 year: 100 mcg/kg (maximum 2 mg) 3–4 times daily
• Child 2–5 years: 1–2 mg, 3–4 times daily
• Child 6–11 years: 2 mg, 3–4 times daily
• Child 12–17 years: 2–4 mg, 3–4 times daily
• Over 18 years: 4 mg (elderly and sensitive patients initially 2 mg), 3–4 times daily, with a maximum single dose of 8 mg (but unlikely to provide much extra benefit or to be tolerated).
Long-acting selective beta2 agonist with corticosteroid.
For asthma, maintenance therapy with WockAIR® 160 mcg/4.5 mcg by inhalation of powder
Adult: Initially 1–2 inhalations twice daily, increased if necessary up to 4 inhalations twice daily; reduced to 1 inhalation daily, dose reduced only if control is maintained.
For asthma, maintenance and reliever therapy with WockAIR® 160 mcg/4.5 mcg by inhalation of powder
Adult: Maintenance 2 inhalations daily in 1–2 divided doses, increased if necessary to 2 inhalations twice daily; 1 inhalation as required, for relief of symptoms, increased if necessary up to 6 inhalations as required, max. 8 inhalations per day; up to 12 inhalations daily can be used for a limited time but medical assessment is recommended.
For chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 70% of predicted (post-bronchodilator) with WockAIR® 160 mcg/4.5 mcg by inhalation of powder
Adult: 2 inhalations twice daily.
For asthma, maintenance therapy with WockAIR® 320 mcg/9 mcg by inhalation of powder
Adult: Initially 1 inhalation twice daily, increased if necessary up to 2 inhalations twice daily; reduced to 1 inhalation daily, dose reduced only if control is maintained.
For chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 70% of predicted (post-bronchodilator) with WockAIR® 320mcg/9 mcg by inhalation of powder
Adult: 1 inhalation twice daily.